You are here: Welcome » Jesse Papenburg

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
jesse_papenburg [2022/04/20 00:25]
liam 		jesse_papenburg [2022/11/12 00:00] (current)
liam [Funding]
Line 17: Line 17:
 ==== McGill University ==== ==== McGill University ====
  
-Papenburg is an Assistant Professor of Paediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at [[McGill University]]. He practices Pediatric Infectious Diseases and Medical Microbiology at the [[Montreal Children's Hospital]] of the [[McGill University Health Centre]].+Papenburg is an Assistant Professor of Paediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at [[McGill University]].((//Jesse Papenburg.// (2021, March 4). McGill Newsroom. https://www.mcgill.ca/newsroom/jesse-papenburg)) He practices Pediatric Infectious Diseases and Medical Microbiology at the [[Montreal Children's Hospital]] of the [[McGill University Health Centre]].((//Jesse Papenburg, MD, FRCPC, Pediatric Infectious Disease Specialist and Medical Microbiologist.// Montreal Children’s Hospital. Retrieved April 19, 2022, from https://www.thechildren.com/departments-and-staff/staff/jesse-papenburg-md-frcpc-pediatric-infectious-disease-specialist-and))
  
 +He is also a clinical investigator for the [[MUHC Vaccine Study Centre]].((//About Us.// (2020, July 23). MUHC Vaccine Study Centre; Wayback Machine. https://archive.ph/R2Pr5))
 +==== COVID-19 Immunity Task Force ====
 +
 +Papenburg is a scientific advisor on the secretariat of the [[COVID-19 Immunity Task Force]].((Labonne, S. //Secretariat.// COVID-19 Immunity Task Force. Retrieved April 19, 2022, from https://web.archive.org/web/20220322055327/https://www.covid19immunitytaskforce.ca/secretariat/)) The CITF collaborates with the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) on vaccine development.((//Final Version Scientific Strategy, Governance, and Operational Plan.// (2020). COVID-19 Immunity Task Force. https://web.archive.org/web/20220120225658/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2020/11/CITF-Strategic-Plan_Final_ENG_FINAL_2.pdf#page=17))
 ===== Research ===== ===== Research =====
  
Line 27: Line 31:
 Papenburg and [[Patricia Fontela]] are co-Primary Investigators in the [[CATCO-Kids]] study, investigating the use of [[hydroxychloroquine]] in children with [[COVID-19]]. The trial is funded by the [[Montreal Children's Hospital Foundation]], and is a spinoff study from the [[CATCO]] trial, which is itself the Canadian branch of the [[SOLIDARITY Trial]].((//Funded Research.// COVID-19 Resources Canada. Retrieved April 19, 2022, from https://archive.ph/htYhS)) ((//Results of MI4 Emergency COVID-19 Research Funding.// (2021, August 23). McGill MI4. https://archive.ph/X6BWG)) Papenburg and Fontela are also both investigators for CATCO, including investigating [[remdesivir]].((Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., & Farjou, G. (2022). //Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.// CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, cmaj.211698. https://doi.org/10.1503/cmaj.211698)) Papenburg and [[Patricia Fontela]] are co-Primary Investigators in the [[CATCO-Kids]] study, investigating the use of [[hydroxychloroquine]] in children with [[COVID-19]]. The trial is funded by the [[Montreal Children's Hospital Foundation]], and is a spinoff study from the [[CATCO]] trial, which is itself the Canadian branch of the [[SOLIDARITY Trial]].((//Funded Research.// COVID-19 Resources Canada. Retrieved April 19, 2022, from https://archive.ph/htYhS)) ((//Results of MI4 Emergency COVID-19 Research Funding.// (2021, August 23). McGill MI4. https://archive.ph/X6BWG)) Papenburg and Fontela are also both investigators for CATCO, including investigating [[remdesivir]].((Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., & Farjou, G. (2022). //Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.// CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, cmaj.211698. https://doi.org/10.1503/cmaj.211698))
  
 +In December 2021, Papenburg appeared in a video promoting [[COVID-19 vaccines]] for children and insisting no concerning long-term effects will occur, published on [[ScienceUpFirst]].((//Dr. Papenburg: Are COVID-19 vaccines safe for kids long-term?// (2021, December 9). ScienceUpFirst. https://archive.ph/HyQ64)) He also appeared in a January 6, 2022 interview discussing segregation of "unvaccinated" people in Quebec.((CBC News. (2022, January 6). //Quebec announces new COVID-19 measures aimed at the unvaccinated.// MSN News. https://web.archive.org/web/20220419224615/https://www.msn.com/en-ca/news/other/quebec-announces-new-covid-19-measures-aimed-at-the-unvaccinated/vi-AASvMIo))
 ==== Influenza ==== ==== Influenza ====
  
Line 33: Line 38:
 ==== RSV ==== ==== RSV ====
  
-Papenburg was an author on an [[RSV]] study funded by the [[Bill & Melinda Gates Foundation]].((Scheltema, N. M., Gentile, A., Lucion, F., Nokes, D. J., Munywoki, P. K., Madhi, S. A., Groome, M. J., Cohen, C., Moyes, J., Thorburn, K., Thamthitiwat, S., Oshitani, H., Lupisan, S. P., Gordon, A., Sánchez, J. F., O’Brien, K. L., Gessner, B. D., Sutanto, A., Mejias, A., & Ramilo, O. (2017). //Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.// The Lancet Global Health, 5(10), e984–e991. https://doi.org/10.1016/S2214-109X(17)30344-3)) ((//University Medical Center Utrecht, Netherlands.// (2016, April). Bill & Melinda Gates Foundation. https://www.gatesfoundation.org/about/committed-grants/2016/04/opp1148988))+Papenburg was an author on an [[RSV]] study funded by the [[Bill & Melinda Gates Foundation]].((Scheltema, N. M., Gentile, A., Lucion, F., Nokes, D. J., Munywoki, P. K., Madhi, S. A., Groome, M. J., Cohen, C., Moyes, J., Thorburn, K., Thamthitiwat, S., Oshitani, H., Lupisan, S. P., Gordon, A., Sánchez, J. F., O’Brien, K. L., Gessner, B. D., Sutanto, A., Mejias, A., & Ramilo, O. (2017). //Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.// The Lancet Global Health, 5(10), e984–e991. https://doi.org/10.1016/S2214-109X(17)30344-3)) ((//University Medical Center Utrecht, Netherlands.// (2016, April). Bill & Melinda Gates Foundation. https://archive.ph/yfvkp))
  
 ==== Funding ==== ==== Funding ====
  
-Papenburg is funded by a career award from [[Fonds de Recherche du Québec]], and funding from the [[Quebec Ministry of Health and Social Services]].((Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). //Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.// Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180)) He has received research funding from the [[CHUM Foundation]] and the [[Canadian Institutes of Health Research]] (CIHR). He has received grants from [[pharmaceutical_companies:MedImmune]] and [[pharmaceutical_companies:Sanofi]], as well as grants and personal fees from [[pharmaceutical_companies:AbbVie]], [[medical_technology_companies:Beckton Dickenson and Company|BD Diagnostics]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Seegene]].((Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). //Guidance on the use of antiviral agents for the 2019–2020 influenza season.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.// medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325)) He has also received consulting fees from [[pharmaceutical_companies:Merck]], and personal fees from [[pharmaceutical_companies:Cepheid]] and [[pharmaceutical_companies:Roche]].((Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). //Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2.// Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301)) ((Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). //Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study.// Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873)) He has also published research funded by the [[Janeway Children's Hospital Foundation]]. He also served on a Scientific Steering Committee for AbbVie.((Papenburg, J., & Harrison, R. (2021, October 27). //Seasonal Influenza Immunization 2021-2022.// National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf))+Papenburg is funded by a career award from [[Fonds de Recherche du Québec]], and funding from the [[Quebec Ministry of Health and Social Services]].((Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). //Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.// Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180)) He has received research funding from the [[CHUM Foundation]] and the [[Canadian Institutes of Health Research]] (CIHR).((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) He has received grants from [[pharmaceutical_companies:MedImmune]] and [[pharmaceutical_companies:Sanofi]], as well as grants and personal fees from [[pharmaceutical_companies:AbbVie]], [[medical_technology_companies:Beckton Dickenson and Company|BD Diagnostics]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Seegene]].((Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). //Guidance on the use of antiviral agents for the 2019–2020 influenza season.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.// medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325)) He has also received consulting fees from [[pharmaceutical_companies:Merck]], and personal fees from [[pharmaceutical_companies:Cepheid]] and [[pharmaceutical_companies:Roche]].((Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). //Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2.// Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301)) ((Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). //Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study.// Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873)) He has also published research funded by the [[Janeway Children's Hospital Foundation]]. He also served on a Scientific Steering Committee for AbbVie.((Papenburg, J., & Harrison, R. (2021, October 27). //Seasonal Influenza Immunization 2021-2022.// National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf)) 
 + 
 +Papenburg appeared in a feature article discussing his many media appearances related to [[COVID-19]], and solicited donations for more COVID-19 research to the [[Montreal Children's Hospital Foundation]].((//The Children’s COVID-19 media authority: Dr. Jesse Papenburg.// Montreal Children’s Hospital Foundation. Retrieved April 19, 2022, from https://web.archive.org/web/20220419225627/https://fondationduchildren.com/en/heroes/the-childrens-covid-19-media-authority-dr-jesse-papenburg))
Back to top